About
Awards
History
Leadership
Board of Directors
Investors and Partners
Pipeline
Cefepime-Taniborbactam
Ceftibuten / VNRX-7145
PBP Inhibitor
VNRX-9945
Publications
Manuscripts
Posters
News & Events
Press Releases
In the News
Events
Careers
Open Positions
#venatorxcares
Contact
Publications
Publications
Manuscripts
Posters
Manuscripts
The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli
Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
MORE MANUSCRIPTS
Posters
Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of chronic hepatitis B virus (HBV) infection
Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases.
Evaluation of the
in vitro
activity of cefepime plus taniborbactam (formerly VNRX-5133) and comparative agents against carbapenem-resistant Enterobacteriaceae.
Oral ceftibuten/VNRX-7145 shows equivalent activity
in vitro
to IV therapeutics against MDR Enterobacteriaceae.
MORE POSTERS
You are using a browser that is not supported. Please consider changing your browser
